Table 4.

CYP3A4 activity and docetaxel and imatinib pharmacokinetics

Parameter	Cycle		P
	1	2
	Mean ± SD (n)*	Mean ± SD (n)*
ERMBT C20min % dose/minute	0.051 ± 0.017 (12)	0.030 ± 0.014(7)	0.016
Docetaxel
Normalized $C_{max}^{\text{a}}$ (μg/ml)	2.6 ± 0.7 (12)	2.2 ± 0.3(7)	0.08
Normalized ${\text{AUC}}_{\text{inf}}^{\text{a}}$ (μg h/ml)	2.9 ± 0.7 (12)	2.8 ± 0.6(7)	0.45
Normalized average ${\text{C}}_{168\text{h}}^{\text{a}}$ (μg/ml)	0.0015 ± 0.0006(12)	0.0017 ± 0.0005(7)	0.088
CL (l/h)	16.3 ± 3.59(12)	18.1 ± 4.35(7)	0.44
T1/2 (h)	45.1 ± 20.0(12)	60.2 ± 31.0(7)	0.23
Imatinib
Normalized $C_{max}^{\text{b}}$ (μg/m)	–	6.5 ± 2.8(7)	–
Tmax (h)	–	5.0 [2.1–7.2](7)	–
Normalized ${\text{AUC}}_{\tau }^{\text{b}}$ (μg/m h)	–	98.6 ± 41.7(7)	–
CL/F (l/h)	–	6.8 ± 2.2(7)	–
Normalized $C_{min,\text{ss}}^{\text{b}}$ (μg/ml)	–	2.6 ± 1.2(12)	–

^*Data is presented as the mean ± SD (n), except T_max which is presented as the median [range] (n)

SD standard deviation, ERMBT erythromycin breath test, C_20min flux of ¹⁴CO₂ at 20 min after administration of the ERMBT, C_max maximum plasma concentration, AUC_inf area under the concentration–time curve from time zero to infinity, CL clearance, T_1/2 half-life, AUC_τ area under the concentration–time curve during the dosing interval, CL/F apparent oral clearance, C_min,ss minimum plasma concentration at steady-state

^aData is normalized to a dose of 25 mg/m²

^bData is normalized to a dose of 600 mg/day